


RESEARCH

Open Access



Genetic polymorphisms of histone methyltransferase *SETD2* predicts prognosis and chemotherapy response in Chinese acute myeloid leukemia patients

Suwei Wang^{1,2}, Xiaoqing Yuan^{1,4}, Yazhen Liu^{1,2}, Kewei Zhu^{1,2}, Peng Chen^{1,2}, Han Yan^{1,5}, Daoyu Zhang^{1,2}, Xi Li^{1,2,3}, Hui Zeng⁶, Xielan Zhao⁶, Xiaoping Chen^{1,2,3}, Gan Zhou^{1,3,6,7*} and Shan Cao^{1,2,3*} 

Abstract

Background: *SETD2*, the single mediator of trimethylation of histone 3 at position lysine 36, has been reported associated with initiation progression and chemotherapy resistance in acute myeloid leukemia (AML). Whether polymorphisms of *SETD2* affect prognosis and chemotherapy response of AML remains elusive.

Methods: Three tag single-nucleotide polymorphisms (tagSNPs) of *SETD2* were genotyped in 579 AML patients by using Sequenom Massarray system. Association of the SNPs with complete remission (CR) rate after Ara-C based induction therapy, overall survival (OS) and relapse-free survival (RFS) were analyzed.

Result: Survival analysis indicated that *SETD2* rs76208147 TT genotype was significantly associated with poor prognosis of AML (TT vs. CC + CT hazard ratio: HR = 1.838, 95% confidence interval (CI) 1.005–3.360, $p = 0.048$). After adjusting for the known prognostic factors including risk stratification, age, allo-SCT, WBC count and LDH count, rs76208147 TT genotype was still associated with OS in the multivariate analysis (TT vs. CC + CT HR = 1.923, 95% CI 1.007–3.675, $p = 0.048$). In addition, after adjusting by other clinical features, patients with rs4082155 allele G carries showed higher rate of complete remission which indicated by CR rate (AG + GG vs. AA odd ratio (OR) = 0.544, 95% CI 0.338–0.876, $p = 0.012$).

Conclusions: *SETD2* genetic polymorphism is associated with AML prognosis and chemotherapy outcome, suggesting the possibility for development in AML diagnostics and therapeutics towards *SETD2*.

Keywords: Acute myeloid leukemia, *SETD2*, Histone 3 lysine 36 trimethylation, SNP, Chemotherapy, Cytarabine

Background

Acute myeloid leukemia (AML) is a genetically and clinically heterogeneous disorder featured by the incomplete maturation of hematopoietic stem cell and the reduction of normal blood counts [1]. Despite great efforts have been made in new therapy development,

chemotherapy with cytarabine and anthracycline remains the current treatment protocols in AML, which conduct complete remission (CR) rates of 70–80% [2]. However, more than half of adult patients and around 80% of elder patients develop into primary refractoriness, relapse, or treatment-related mortality [3]. In addition, tremendous individual variability in prognosis varies greatly among patients: 5-year survival varies from 18 to 82%, and relapse rate varies from 33 to 80%, which can be partly explained by disease subtype, age, somatic mutations, gene expression abnormalities, and other molecular alterations.

*Correspondence: zhougan@csu.edu.cn; caoshan2016@163.com

¹ Department of Clinical Pharmacology, Institute of Clinical Pharmacology, Central South University, 110 Xiangya Road, Changsha, Hunan 410008, People's Republic of China ⁷ National Institution of Drug Clinical Trial, Xiangya Hospital, Central South University, 110 Xiang Ya Road, Changsha, Hunan 410078, People's Republic of China
Full list of author information is available at the end of the article



Genetic variants in those, such as in *NPML*, *FLT3-ITD*, *CEBPA*, *WT1* have been verified to be marks of prognosis [4–6], however, these factors can only explain part of individual variants for AML.

Recent studies have underscored the significant role of epigenetic mechanisms in chemotherapy sensitivity and disease prognosis of AML. Such as DNA (cytosine-5)-methyltransferase 3 alpha (*DNMT3A*) R882 mutations, which give rise to focal hypomethylation phenotype, were associated with inferior prognosis in AML [7, 8]. Mutations in Ten–eleven-translocation (TET)-enzymes (*TET2*), which catalyzed the oxidation of 5-methylcytosine to 5-hydroxymethylcytosine (5hmC), confers unfavorable prognostic factor in AML patients with intermediate-risk cytogenetics [9].

SETD2 belongs to a superfamily of lysine methyltransferase, which is a solely H3K36 trimethylation-methyltransferase in mammals. H3K36 trimethylation has also been implicated in a diverse of cellular biology functions, including transcriptional activation, alternative splicing, dosage compensation, DNA replication and repair, and homologous recombination [10]. *SETD2* is a 2-hit tumor suppressor gene, for loss-of-function mutations and deletions were detected in a series of tumor types, most notably in clear cell renal cell cancer (ccRCC) [11] and high-grade gliomas [12] and subsequently presents in a subset of patients with acute lymphoblastic leukemia [13] and acute myeloid leukemia [14]. Most of mutations or abnormalities of *SETD2* has been reported to be associated with a worse outcome among patients with ccRCC suggested a protection value of *SETD2* [15]. Moreover, a selective enrichment of *SETD2* inactivating mutation in relapsed acute leukemia indicated an association with chemoresistance [16]. However, whether single-nucleotide polymorphisms (SNPs) in *SETD2* related to disease progression and drug response remains unknown.

In the present study, we performed the candidate gene association study to find out whether *SETD2* SNPs correlated with AML survival and chemotherapy response, which will explore factors leading to individual difference in AML prognosis and will provide new directions for new treatment.

Materials and methods

Clinical analysis sample

579 Chinese Han patients were recruited from the Department of Hematology of Xiangya Hospital from May 2009 to December 2017. All patients were diagnosed and classified based on the FAB criteria. The exclusion criteria were (1) M3 subtype, because of its specific treatment and outcomes. (2) Patients with serious diseases or other cancers, secondary leukemia and those with missing data (e.g. cytogenetics or molecular abnormalities). (3) Patients failed to follow-up were eliminated in this study. The detail therapeutic protocols were described elsewhere [17–19]. Complete remission (CR) was used to assess drug response. CR was defined according to the international recommendations, including no clinical presentation of leukemia, no evidence of extramedullary disease, bone marrow blasts < 5%, neutrophils counts > $1.0 \times 10^9/L$, and platelets counts > $100 \times 10^9/L$ after chemotherapy [20]. Overall survival (OS) and relapse free survival (RFS) were used as disease outcomes and events were defined as any relapse or death in agreement with the criteria as previously described. All survival end points were censored at the date of last follow-up when relapse or death was not observed [21].

This study was approved by the Ethics Committee of Institute of Clinical Pharmacology of Central South University (Register No. CTXY-120025-2). Clinical study admission (Registration Number: ChiCTR-PPC-14005297) was approved by the Chinese Clinical Trial Register. Written informed consent was obtained from each patient in accordance with the recommendations of the Declaration of Helsinki and its later amendments.

TagSNPs selection and genotyping and haplotypes

The following criteria were used to select the tagSNPs of *SETD2*. First, we chose a minor allele frequency (MAF) > 0.1 in the south Chinese population as the target according to 1000 human genomes database (<https://www.ncbi.nlm.nih.gov/variation/tools/1000genomes/>). Then we examined linkage disequilibrium analysis by setting r^2 threshold at 0.8. Three tagSNPs with missense mutation were selected to represent each block (Table 1, Additional file 1: Figure S1). Polyphen database (<http://genetics.bwh.harvard.edu>) was used to predict potential

Table 1 Features of three selected tag SNP from *SETD2*

SNP	Position	Alleles	Variation	MAF	Chi square	p^{HW}
rs4082155	3:47083895	A > G	Exon12 (Leu 1962 Pro)	0.47	0.21	0.90
rs6767907	3:47121171	G > A	Exon3 (Asn 1155 Lys)	0.35	0.44	0.80
rs76208147	3:47121396	C > T	Exon3 (Met 1080 Ile)	0.13	5.37	0.07

structural and functional change of the candidate SNPs and expression quantitative trait locus (eQTL) database (<https://gtexportal.org/home/>) was used to predict the potential influence of the SNPs on expression the corresponding genes (Additional file 2: Figure S2).

Genomic DNA was extracted from peripheral blood cells using E.Z.N.A.VR SQ Blood DNA Kit II (Omega Bio-Tek) according to the supplied protocol. SNP genotyping was conducted by allele-specific matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry (Sequenom, San Diego, CA). About 10% of the samples were randomly selected to validate the genotypes by Sanger sequencing. The results reached to a 100% compliance. Three tagSNPs of *SETD2*, (rs4082155, rs6767907, rs76208147) were finally selected for further study.

Statistical analysis

Statistical analysis was carried out by the software SPSS version 20.0 (SPSS INC. Chicago, IL, USA). χ^2 test was used to determine whether genotype distribution of the SNPs were in agreement with Hardy–Weinberg equilibrium. The Kaplan–Meier curves and univariate Cox regression analysis were depicted to illustrate the profiles of OS/RFS. The independent significant factors were adjusted by multivariable analysis, the Cox proportional hazards model, including clinical factors and *SETD2* SNPs. Sensitivity analyses were conducted on CR rate. Logistic regression were used to evaluate the association between genotypes and chemotherapy response. A limited backward-selection procedure used to adjust the potential confounding covariates, including clinical factors. Statistical significance was accepted when $p < 0.05$ and defined two sides.

Results

Baseline features and overall CR status of the AML patients

The basic and clinical characteristics of the 579 AML patients in this study were recorded in Table 2. The median age of the patients was 43 (range 14–79) years old. Among these patients, 313 were male and 266 were female. The median number of WBC was $14.6 \times 10^9/L$ and the mean serum level of LDH was 363.5 U/L at diagnosis. Other important clinical information was also summarized in Table 2. All patients were classified into seven subtypes on the basis of FAB criteria. M3 subtype ones were ruled out because of its specific therapeutic strategy and outcome. M2 was the most common subtype (45.25%), followed by M5 (19.69%). According to cytogenetics and molecular abnormalities, 90, 262, and 112 patients were stratified as low, intermediate and high risk, respectively. A total of 368 patients (63.6%) achieved CR after one or two courses of chemotherapy, and CR

Table 2 Basic and clinical characteristics of the AML patients in this study (n = 579)

Characteristics	Value
Age at diagnosis, median (range) ^a	43 (14–79)
Gender	
Male	313 (54.1)
Female	266 (45.9)
WBC count at diagnosis ($10^9/L$) ^a	14.6 (0.5–436.2)
RBC count at diagnosis ($10^9/L$) ^a	2.2 (0.62–4.98)
Hemoglobin at diagnosis (g/L) ^a	72 (27–155)
Platelets count at diagnosis ($10^9/L$) ^a	34 (2–1344)
Neutrophil count at diagnosis ($10^9/L$) ^a	2 (0–250)
LDH at diagnosis (U/L) ^a	363.5 (17.0–9289.0)
Bone marrow blasts at diagnosis (%) ^a	71.0 (17.5–99.0)
Peripheral blood blasts at diagnosis (%) ^a	60.0 (5.0–96.0)
FBA subtype (n, %)	
M0	1 (0.17)
M1	25 (4.23)
M2	262 (45.25)
M4	98 (16.92)
M5	114 (19.69)
M6	12 (2.07)
M7	1 (0.17)
Unknown	66 (11.40)
Allo-SCT (n, %)	
Yes	84 (14.51)
No	495 (85.49)
Cytogenetics and molecular stratification	
Low risk (n, %)	90 (15.54)
Intermediate risk (n, %)	262 (45.25)
High risk (n, %)	112 (19.34)
Unknown	115 (19.86)


Allo-SCT allogeneic hematopoietic stem cell transplantation, AML acute myeloid leukemia, FBA subtypes French–Britain–American subtypes, LDH lactate dehydrogenase, RBC red blood cell, WBC white blood cell

^a Data represents median and the range

could not be evaluated accurately for 33 (5.7%) patients due to insufficiencies in clinical evidence. Eighty-four (14.51%) patients received hematopoietic stem cell transplantation. All patients were followed up with a median follow-up period of 554 days (range 17–4742 days).

SETD2 rs76208147 is associated with overall survival of AML patients

Kaplan–Meier survival analysis of this series showed that *SETD2* rs76208147 rare homozygous genotype TT were associated with a worse survival compared to the common homozygous genotype CC ($p = 0.024$; Fig. 1). Because there was no significant difference of overall survival (OS) between patients with CC and CT, we combined the C allele carriers into one group to establish a



recessive model. In the recessive model, rs7620147 TT genotype showed a significant poorer OS than individuals with C alleles ($p=0.023$; Fig. 1). Univariate results showed that *SETD2* rs76208147 TT genotype was associated with a worse OS compared with the carriers of

CC genotype (TT vs. CC hazard ratio: HR=1.836, 95% confidence interval (CI) 1.001–3.369, $p=0.049$; Table 3). As compared with patients carrying rs76208147 C allele (CC+CT), hazard ratio of OS for patients with TT genotype was 1.838 (95% CI 1.005–3.360, $p=0.048$; Table 3). The median overall survival time of the patients with CC+CT genotypes was 885 days (95% CI 697–1073 days), which was significantly longer than those with TT genotype (Median OS=395 days, 95% CI 71–718 days).

After adjusting for the known prognostic factors including risk stratification, age, allo-SCT, WBC count and LDH count (adjusted $p<0.001$, Additional file 3: Table S1), rs76208147 TT genotype was still associated with worse OS in the multivariate analysis (TT vs. CC+CT HR=1.923, 95% CI 1.007–3.675, $p=0.048$, Table 3).

However, other tagSNPs, rs4082155 and rs6767907 did not associated with OS of AML patients in univariate analysis (Table 3). When RFS was used for endpoint, no significantly tagSNPs of *SETD2* were observed through univariate and multivariate analysis.

Candidate SNPs are associated with AML Ara-C based chemotherapy

The CT genotype of rs76208147 showed lower chemotherapy resistant risk compare with CC genotype (OR=0.567, 95% CI 0.35–0.919, $p=0.021$, Table 4). The CR rate were 64.7% and 76.4% for CC and CT genotypes, respectively. This SNP did not passed the correction by adjusted for age, risk stratification, LDH and WBC (adjusted $p<0.05$, Additional file 4: Table S2) in logistic regression analysis. However, when rs76208147

Table 3 Univariate and multivariate Cox regression analysis of SNPs associated with AML overall survival (OS)

Genotype	n	Mean ± SE (day)	Median (range, day)	HR (95% CI)	p	HR (95% CI) ^a	p ^a
rs4082155							
AA	148	1897 ± 293	926 (663–1189)	1.00 (reference)			
AG	262	1264 ± 81	721 (478–964)	1.148 (0.867–1.520)	0.335	1.074 (0.797–1.447)	0.638
GG	120	1300 ± 114	1015 (599–1431)	1.014 (0.724–1.420)	0.989	0.989 (0.690–1.418)	0.953
rs6767907							
GG	65	1717 ± 224	817 (608–1026)	1.00 (reference)			
GA	236	1319 ± 85	735 (356–1114)	0.913 (0.714–1.167)	0.466	1.243 (0.882–1.880)	0.302
AA	229	1338 ± 162	1137 (411–1862)	1.047 (0.880–1.246)	0.602	1.261 (0.833–1.910)	0.273
rs76208147							
CC	406	1844 ± 195	817 (563–1071)	1.00 (reference)			
CT	109	1175 ± 101	1000 (697–1302)	1.001 (0.751–1.334)	0.995	1.131 (0.83–1.54)	0.428
TT	15	601 ± 146	395 (71–718)	1.836 (1.001–3.369)	0.049*	1.736 (0.84–3.58)	0.135
CC+CT	515	1806 ± 182	885 (697–1073)			1.00 (reference)	
TT	15	601 ± 146	395 (71–718)	1.838 (1.005–3.360)	0.048*	1.923 (1.007–3.675)	0.048*

* $p<0.05$

^a Adjusted for risk stratification, age, allo-SCT, WBC count and LDH count

Table 4 Comparison of CR rate among genotypes after two courses of Ara-C based chemotherapy

Genotype	Total (n)	CR (n, %)	Non-CR (n, %)	OR (95% CI)	p	OR (95% CI) ^a	p ^a
rs4082155							
AA	157	96 (61.1%)	61 (38.9%)	1.00 (reference)		1.00 (reference)	
AG	266	184 (69.2%)	82 (30.8%)	0.701 (0.464–1.060)	0.092	0.562 (0.340–0.931)	0.025*
GG	123	88 (71.5%)	35 (28.5%)	0.626 (0.377–1.039)	0.07	0.501 (0.265–0.946)	0.033*
AA	157	96 (61.1%)	61 (38.9%)	1.00 (reference)		1.00 (reference)	
AG + GG	389	272 (69.9%)	117 (30.1%)	0.677 (0.460–0.997)	0.048*	0.544 (0.338–0.876)	0.012*
rs6767907							
GG	237	155 (65.4%)	82 (34.6%)	1.00 (reference)		1.00 (reference)	
GA	242	171 (70.7%)	71 (29.3%)	0.698 (0.396–1.230)	0.213	0.668 (0.323–1.379)	0.275
AA	67	42 (62.7%)	25 (37.3%)	0.889 (0.506–1.560)	0.681	1.126 (0.548–2.317)	0.746
rs76208147							
CC	422	273 (64.7%)	149 (35.3%)	1.00 (reference)		1.00 (reference)	
CT	110	84 (76.4%)	26 (23.6%)	0.567 (0.350–0.919)	0.021*	0.600 (0.342–1.053)	0.075
TT	14	11 (78.6%)	3 (21.2%)	0.500 (0.137–1.819)	0.293	0.545 (0.114–2.604)	0.447

* $p < 0.05$ ^a Adjusted for age, risk stratification, LDH and WBC

TT genotype was taken into account, the p value failed to meet the statistically difference (OR = 0.500, 95% CI 0.14–1.82, $p = 0.293$). This may result from the small sample size, for only three patients involved in the non-CR group with TT genotype. To be noted, homozygous carriers of the allele T has the same tendency with CT genotype indicated by the percentage of CR patients in TT genotype is much higher than CC genotype.

For the *SETD2* rs4082155, allele G carriers showed significant higher sensitivity of chemotherapy than AA carriers (GG + AG vs. AA: OR = 0.677, 95% CI 0.460–0.997, $p = 0.048$) in the dominant model. Logistic regression analysis showed significant associations of risk stratification, age, pretreatment WBC counts and LDH levels with non-CR risk (Additional file 4: Table S2). When adjusted by these risk factors, notably, rs4082155 allele G carriers was still significantly affected chemotherapy sensitivity. Compared with AA genotype, both AG and GG genotype exhibited lower risk of chemoresistance (AG vs. AA: OR = 0.562, 95% CI 0.340–0.931, $p = 0.025$; GG vs. AA: OR = 0.501, 95% CI 0.265–0.946, $p = 0.033$, Table 4). After combining AG and GG genotypes into one group to create a dominant model, rs4082155 allele G carriers indicated more significant higher chemotherapy sensitivity than AA genotype (AG + GG vs. AA: OR = 0.544, 95% CI 0.338–0.876, $p = 0.012$). In the carriers of three genotypes of rs4082155, the ratio of complete remission was 61.1% (AA), 69.2% (AG), and 71.5% (GG) respectively.

Haplotype analysis

We further studied the haplotype of these three SNPs of *SETD2* using PHASE 2.0 software and analyzed its

association with clinical outcome and chemotherapy. Three haplotypes with frequencies higher than 5% were selected. The frequencies of haplotypes AGC (haplotype 1), GAC (haplotype 2), GGT (haplotype 3) were 53.7%, 34.4%, 11.9%, respectively. Haplotype GGT with one or two copy number presents better chemotherapy response compared with no copy number (OR: 0.576, 95% CI 0.38–0.88, $p = 0.01$, Table 5). No significant association was observed between chemotherapy and other haplotypes. The association between these three haplotypes and OS/RFS was analyzed by log-rank test in univariate analysis. However, no haplotype can be a predictable factor for OS or RFS of patients.

Discussion

In this study, we studied the association between *SETD2* tagSNPs with chemosensitivity response to Ara-C based therapy as well as disease prognosis in Chinese AML patients for the first time. We found that *SETD2* rs76208147 TT genotype predicted worse OS in the

Table 5 Haplotype analysis associated with chemosensitivity in *SETD2* polymorphism

Haplotype	CR (n, %)	NR (n, %)	χ^2	p	OR (95% CI)
AGC	188 (50.9%)	102 (56.6%)	2.871	0.090	0.803 (0.623–1.035)
GAC	127 (34.3%)	62 (34.5%)	0.000	0.998	1.000 (0.767–1.303)
GGT	51 (13.9%)	16 (8.4%)	6.679	0.010	1.738 (1.138–2.652)

AML patients, while the *SETD2* rs4082155 AA genotype were associated with chemoresistance after Ara-C based therapy. Moreover, haplotype with one or two copies of GGT showed better chemotherapy response compare with individuals with no copies.

The *SETD2* gene encodes a 230 kDa protein that is non-redundantly responsible for trimethylation of lysine 36 on histone H3 (H3K36me3), a critical mark that is involved in various important cellular processes such as transcriptional elongation, alteration splicing, mismatch repair regulation and homologous recombination repair [22–27]. Recently, *SETD2* was identified as tumor suppressor, as loss-of-function mutation with *SETD2* has been discovered in various tumors, including ccRCC, lung adenocarcinoma, gliomas, AML, ALL, and mastocytosis [12, 28–32]. In addition, loss-of-function mutation in *SETD2* and/or decreased H3K36me3 levels have been linked to poor clinical prognosis in lung cancer and ccRCC [15, 33]. In AML, *SETD2* mutations are recurrent events and are associated with chromosomal abnormalities that are known to be driver mutations in leukemogenesis, such as MLL-rearrangement [14]. In the presence of chromosomal translocation, such as MLL-rearrangement, knockdown of *SETD2* promotes initiation as well as progression of tumor by expediting the potential of self-renewal of leukemic stem cell [14]. Notably, under normal hematopoietic condition, *SETD2* is required to maintain self-renewal capability of hematopoietic stem cell, *SETD2*-deleted HSCs gives rise to malignant transformation eventually [34]. Consistent with our findings, *SETD2* rs76208147 TT genotype indicates worse prognosis of AML patient, which underlying mechanism warrants further investigation.

Recently, it is well accepted that *SETD2* was associated with chemotherapy sensitivity. Studies have identified the enrichment of mutations in *SETD2* in relapsed acute lymphoblastic leukemia and MLL-rearranged acute leukemia [16]. In addition, *SETD2* mutations led to resistance to DNA-damaging agents, cytarabine, 6-thioguanine, doxorubicin, and etoposide, but not to a non-DNA damaging agent via impairing DNA damage recognition [35]. Moreover, acquired loss-of-function mutations in *SETD2* enable metastatic non-small cell lung cancer to resist to cisplatin [36]. All of these reports suggested that *SETD2* exerted a subtle impact on the DNA mismatch repair (MMR) machinery [37]. It has been reported that MSH6, which is an essential component of the MMR machinery localizes to chromatin by binding to the H3K36 trimethyl mark that *SETD2* makes. *SETD2* knockdown has been shown to give rise to mislocalization of MSH6 and microsatellite instability and a mutator phenotype in several cell types. There are at least

two possible explanations to link *SETD2* inactivation to the survival of leukemia cell. First, a mutator phenotype induced by *SETD2* inactivation could increase the mutational diversity and thus, adaptability of the leukemia, leading to clonal survival. Two, since intact MMR is important for triggering apoptosis and/or cell cycle arrest in response to many DNA damaging chemotherapies, *SETD2* loss may lead to chemotherapy tolerance [35]. To be mentioned, the function of *SETD2* is also involved in homologous recombination which deficiency have generally led to sensitivity to DNA-damaging agents, such as cisplatin [24]. That being said, the impact of *SETD2* alteration on homologous recombination require further investigation.

SETD2 was discovered because of its capability to catalyze H3K36 trimethyltransferase, and major researches have been confined to its role of histone modification. But, in recent studies it has become apparent that *SETD2* exerts diverse functions that unrelated to histone modification. For instance, it has been reported that *SETD2* directly mediates STAT1 methylation on lysine 525, which amplifies the antiviral immunity of IFN- α [38], and α -tubulin methylation on lysine 40, which maintains genomic stability through microtubule methylation [39]. Taken together, the contributions of these additional functions of *SETD2* on prognosis and treatment of AML remain to be fully elucidated.

There are several limitations in the present study. First, the outcomes of our study failed to undergo multiple test adjusting, P values lost statistical significance when Bonferroni correction was performed possibly due to the limited sample size included in our study. Second, Ara-C response is affected by various genetic factors, the contribution of single unique gene to the drug exposure might be limited.

Conclusion

In conclusion, our study showed for the first time that SNPs in epigenetics modulator genes such as *SETD2* are associated with drug sensitivity to Ara-C based chemotherapy and prognosis in Chinese AML patients. As the factors applicable for prediction of AML outcome are still limited, our findings provide insightful information that SNPs in epigenetic modulator may be considered as potential markers in evaluation of AML outcome. For *SETD2* involving in tumor initiation, progression as well as chemosensitivity through different mechanism. Functional studies are now warranted to illustrate the exact biological function of *SETD2* in AML, but our data add to a growing body of evidence suggesting a role for *SETD2* and H3K36me3 in AML that may be developed for the exploitation of novel therapeutic target.

Additional files

Additional file 1: Figure S1. Position of three SNPs in SETD2.

Additional file 2: Figure S2. eQTL analysis of SETD2 polymorphisms.

Additional file 3: Table S1. Multivariate Cox regression analysis of clinical characteristics impacting AML OS.

Additional file 4: Table S2. Unconditional logistic regression analysis of clinical features related to non-CR risk in AML.

Authors' contributions

WSW made main contributions to specimen collection, sorting date, date analysis; YXQ analyzed the data; LYZ, ZKW, CP, YH and ZHY assisted in specimen collection, acquisition of clinical date and obtaining the follow-up information; LX gave useful advice; ZH, ZXL helped to collect specimen smoothly; CXP helped to design research and gave guidance; CS and ZG provided substantial guidance, designed the research and drafted and revised manuscript. All authors read and approved the final manuscript.

Author details

¹ Department of Clinical Pharmacology, Institute of Clinical Pharmacology, Central South University, 110 Xiangya Road, Changsha, Hunan 410008, People's Republic of China. ² Hunan Key Laboratory of Pharmacogenetics, Changsha, Hunan 410078, People's Republic of China. ³ National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, People's Republic of China. ⁴ Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, People's Republic of China. ⁵ Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410078, People's Republic of China. ⁶ Department of Hematology, Xiangya Hospital, Central South University, Changsha, Hunan 410078, People's Republic of China. ⁷ National Institution of Drug Clinical Trial, Xiangya Hospital, Central South University, 110 Xiang Ya Road, Changsha, Hunan 410078, People's Republic of China.

Acknowledgements

The authors would like to thank Prof. Hui Zeng, Zhi-ping Jiang, Xie-lan Zhao for unselfish assistance with collecting specimen and acquiring clinical date.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

The datasets supporting the conclusions of this article are included within the article (and its additional files).

Consent for publication

Not applicable.

Ethics approval and consent to participate

This study was approved by the Ethics Committee of Institute of Clinical Pharmacology, Central South University (Registration Number: CTXY-120025-2). Clinical study admission (Registration Number: ChiCTR-PPC-14005297) was approved by the Chinese Clinical Trial Register and informed consent was obtained from each patient or their family members.

Funding

This project was supported by Chinese National Science Foundation (No. 81503073 No. 81170091, No. 81422052), Special topic of the major subject of national science and technology (2012ZX09509-107) National Science and Technology Major Project (2017ZX09304014).

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 27 December 2018 Accepted: 15 March 2019

Published online: 28 March 2019

References

- Ferrara F, Schiffer CA. Acute myeloid leukaemia in adults. *Lancet*. 2013;381:484–95.
- Derolf AR, Kristinsson SY, Andersson TM, Landgren O, Dickman PW, Bjorkholm M. Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005. *Blood*. 2009;113:3666–72.
- McGregor AK, Moulton D, Bown N, Cuthbert G, Bourn D, Mathew S, Dang R, Mounter P, Jones G. Incidence and outcomes for adults diagnosed with acute myeloid leukemia in the north of England: a real world study. *Leuk Lymphoma*. 2016;57:1575–84.
- Zhang DY, Yan H, Cao S, Zhang W, Li XL, Zeng H, Chen XP. Wilms Tumor 1 rs16754 predicts favorable clinical outcomes for acute myeloid leukemia patients in South Chinese population. *Leuk Res*. 2015;39:568–74.
- Lu JW, Wang AN, Liao HA, Chen CY, Hou HA, Hu CY, Tien HF, Ou DL, Lin LI. Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD). *Cancer Lett*. 2016;376:218–25.
- Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, Potter NE, Heuser M, Thol F, Bolli N, Gundem G, Van Loo P, Martincorena I, Ganly P, Mudie L, McLaren S, O'Meara S, Raine K, Jones DR, Teague JW, Butler AP, Greaves MF, Ganser A, Dohner K, Schlenk RF, Dohner H, Campbell PJ. Genomic classification and prognosis in acute myeloid leukemia. *N Engl J Med*. 2016;374:2209–21.
- Ribeiro AF, Pratorcorona M, Eperlinck-Verschueren C, Rockova V, Sanders M, Abbas S, Figueroa ME, Zeilemaker A, Melnick A, Lowenberg B, Valk PJ, Delwel R. Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia. *Blood*. 2012;119:5824–31.
- Yuan XQ, Zhang DY, Yan H, Yang YL, Zhu KW, Chen YH, Li X, Yin JY, Li XL, Zeng H, Chen XP. Evaluation of DNMT3A genetic polymorphisms as outcome predictors in AML patients. *Oncotarget*. 2016;7:60555–74.
- Chou WC, Chou SC, Liu CY, Chen CY, Hou HA, Kuo YY, Lee MC, Ko BS, Tang JL, Yao M, Tsay W, Wu SJ, Huang SY, Hsu SC, Chen YC, Chang YC, Kuo YY, Kuo KT, Lee FY, Liu MC, Liu CW, Tseng MH, Huang CF, Tien HF. TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. *Blood*. 2011;118:3803–10.
- Wagner EJ, Carpenter PB. Understanding the language of Lys36 methylation at histone H3. *Nat Rev Mol Cell Biol*. 2012;13:115–26.
- Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G, Butler A, Davies H, Edkins S, Hardy C, Latimer C, Teague J, Andrews J, Barthorpe S, Beare D, Buck G, Campbell PJ, Forbes S, Jia M, Jones D, Knott H, Kok CY, Lau KW, Leroy C, Lin ML, McBride DJ, Maddison M, Maguire S, McLay K, Menzies A, Mironenko T, Mulderrig L, Mudie L, O'Meara S, Pleasance E, Rajasingham A, Shepherd R, Smith R, Stebbings L, Stephens P, Tang G, Tarpey PS, Turrell K, Dykema KJ, Khoo SK, Petillo D, Wondergem B, Anema J, Kahnski RJ, Teh BT, Stratton MR, Futreal PA. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. *Nature*. 2010;463:360–3.
- Fontebasso AM, Schwartzentruber J, Khuong-Quang DA, Liu XY, Sturm D, Korshunov A, Jones DT, Witt H, Kool M, Albrecht S, Fleming A, Hadjadj D, Busche S, Lepage P, Montpetit A, Staffa A, Gerges N, Zakrzewska M, Zakrzewski K, Liberski PP, Hauser P, Garami M, Klekner A, Bognar L, Zadeh G, Faury D, Pfister SM, Jabado N, Majewski J. Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas. *Acta Neuropathol*. 2013;125:659–69.
- Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D, Easton J, Chen X, Wang J, Rusch M, Lu C, Chen SC, Wei L, Collins-Underwood JR, Ma J, Roberts KG, Pounds SB, Ulyanov A, Becksfors J, Gupta P, Huether R, Kriwacki RW, Parker M, McGoldrick DJ, Zhao D, Alford D, Espy S, Bobba KC, Song G, Pei D, Cheng C, Roberts S, Barbato MI, Campana D, Coustan-Smith E, Shurtleff SA, Raimondi SC, Kleppe M, Cools J, Shimano KA, Hermiston ML, Doulatov S, Eppert K, Laurenti E, Notta F, Dick JE, Basso G, Hunger SP, Loh ML, Devidas M, Wood B, Winter S, Dunsmore KP, Fulton RS, Fulton LL, Hong X, Harris CC, Dooling DJ, Ochoa K, Johnson KJ, Obenaus JC, Evans WE, Pui CH, Naeve CW, Ley TJ, Mardis ER, Wilson RK, Downing JR, Mullighan CG. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. *Nature*. 2012;481:157–63.

14. Zhu X, He F, Zeng H, Ling S, Chen A, Wang Y, Yan X, Wei W, Pang Y, Cheng H, Hua C, Zhang Y, Yang X, Lu X, Cao L, Hao L, Dong L, Zou W, Wu J, Li X, Zheng S, Yan J, Zhou J, Zhang L, Mi S, Wang X, Zhang L, Zou Y, Chen Y, Geng Z, Wang J, Zhou J, Liu X, Wang J, Yuan W, Huang G, Cheng T, Wang QF. Identification of functional cooperative mutations of SETD2 in human acute leukemia. *Nat Genet.* 2014;46:287–93.
15. Liu W, Fu Q, An H, Chang Y, Zhang W, Zhu Y, Xu L, Xu J. Decreased expression of SETD2 predicts unfavorable prognosis in patients with nonmetastatic clear-cell renal cell carcinoma. *Medicine.* 2015;94:e2004.
16. Mar BG, Bullinger LB, McLean KM, Grauman PV, Harris MH, Stevenson K, Neuberg DS, Sinha AU, Sallan SE, Silverman LB, Kung AL, Lo Nigro L, Ebert BL, Armstrong SA. Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia. *Nat Commun.* 2014;5:3469.
17. Zhu KW, Chen P, Zhang DY, Yan H, Liu H, Cen LN, Liu YL, Cao S, Zhou G, Zeng H, Chen SP, Zhao XL, Chen XP. Association of genetic polymorphisms in genes involved in Ara-C and dNTP metabolism pathway with chemosensitivity and prognosis of adult acute myeloid leukemia (AML). *J Transl Med.* 2018;16:90.
18. Chen P, Zhu KW, Zhang DY, Yan H, Liu H, Liu YL, Cao S, Zhou G, Zeng H, Chen SP, Zhao XL, Yang J, Chen XP. Influence of UGT1A1 polymorphisms on the outcome of acute myeloid leukemia patients treated with cytarabine-base regimens. *J Transl Med.* 2018;16:197.
19. Yan H, Zhang DY, Li X, Yuan XQ, Yang YL, Zhu KW, Zeng H, Li XL, Cao S, Zhou HH, Zhang W, Chen XP. Long non-coding RNA GAS5 polymorphism predicts a poor prognosis of acute myeloid leukemia in Chinese patients via affecting hematopoietic reconstitution. *Leuk Lymphoma.* 2017;58:1948–57.
20. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Lowenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD, International Working Group for Diagnosis, S. o. R. C. T. O., and Reporting Standards for Therapeutic Trials in Acute Myeloid, L. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. *J Clin Oncol.* 2003;21:4642–9.
21. Zhang DY, Yuan XQ, Yan H, Cao S, Zhang W, Li XL, Zeng H, Chen XP. Association between DCK 35708 T>C variation and clinical outcomes of acute myeloid leukemia in South Chinese patients. *Pharmacogenomics.* 2016;17:1519–31.
22. Li GM. Decoding the histone code: role of H3K36me3 in mismatch repair and implications for cancer susceptibility and therapy. *Cancer Res.* 2013;73:6379–83.
23. Pfister SX, Markkanen E, Jiang Y, Sarkar S, Woodcock M, Orlando G, Mavrommati I, Pai CC, Zalmas LP, Drobnitzky N, Dianov GL, Verrill C, Macaulay VM, Ying S, La Thangue NB, D'Angiolella V, Ryan AJ, Humphrey TC. Inhibiting WEE1 selectively kills histone H3K36me3-deficient cancers by dNTP starvation. *Cancer Cell.* 2015;28:557–68.
24. Carvalho S, Vitor AC, Sridhara SC, Martins FB, Raposo AC, Desterro JM, Ferreira J, de Almeida SF. SETD2 is required for DNA double-strand break repair and activation of the p53-mediated checkpoint. *Elife.* 2014;3:e02482.
25. Aymard F, Bugler B, Schmidt CK, Guillou E, Caron P, Briois S, Iacovoni JS, Daburon V, Miller KM, Jackson SP, Legube G. Transcriptionally active chromatin recruits homologous recombination at DNA double-strand breaks. *Nat Struct Mol Biol.* 2014;21:366–74.
26. Neri F, Rapelli S, Krepelova A, Incarnato D, Parlato C, Basile G, Maldotti M, Anselmi F, Oliviero S. Intragenic DNA methylation prevents spurious transcription initiation. *Nature.* 2017;543:72–7.
27. Dronamraju R, Jha DK, Eser U, Adams AT, Dominguez D, Choudhury R, Chiang YC, Rathmell WK, Emanuele MJ, Churchman LS, Strahl BD. Set2 methyltransferase facilitates cell cycle progression by maintaining transcriptional fidelity. *Nucleic Acids Res.* 2018;46:1331–44.
28. Duns G, van den Berg E, van Duivenbode I, Osinga J, Hollema H, Hofstra RM, Kok K. Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma. *Cancer Res.* 2010;70:4287–91.
29. Wang Q, Cheng T. Evidences for mutations in the histone modifying gene SETD2 as critical drivers in leukemia development. *Sci China Life Sci.* 2014;57:944–6.
30. Parker H, Rose-Zerilli MJ, Larrayoz M, Clifford R, Edelmann J, Blakemore S, Gibson J, Wang J, Ljungstrom V, Wojdacz TK, Chaplin T, Roghanian A, Davis Z, Parker A, Tausch E, Ntoufa S, Ramos S, Robbe P, Alsolami R, Steele AJ, Packham G, Rodriguez-Vicente AE, Brown L, McNicholl F, Forconi F, Pettitt A, Hillmen P, Dyer M, Cragg MS, Chelala C, Oakes CC, Rosenquist R, Stamatopoulos K, Stilgenbauer S, Knight S, Schuh A, Oscier DG, Streford JC. Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia. *Leukemia.* 2016;30:2179–86.
31. Martinelli G, Mancini M, De Benedittis C, Rondoni M, Papayannidis C, Manfrini M, Meggendorfer M, Calogero R, Guadagnuolo V, Fontana MC, Bavaro L, Padella A, Zago E, Pagano L, Zanotti R, Scaffidi L, Specchia G, Albano F, Merante S, Elena C, Savini P, Gangemi D, Tosi P, Ciceri F, Poletti G, Riccioni L, Morigi F, Delledonne M, Haferlach T, Cavo M, Valent P, Soverini S. SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis. *Leukemia.* 2018;32:139–48.
32. Walter DM, Venancio OS, Buza EL, Tobias JW, Deshpande C, Gudiel AA, Kim-Kiselak C, Cicchini M, Yates TJ, Feldser DM. Systematic in vivo inactivation of chromatin-regulating enzymes identifies Setd2 as a potent tumor suppressor in lung adenocarcinoma. *Cancer Res.* 2017;77:1719–29.
33. Kadara H, Choi M, Zhang J, Parra ER, Rodriguez-Canales J, Gaffney SG, Zhao Z, Behrens C, Fujimoto J, Chow C, Yoo Y, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach J, Kaftan E, Townsend JP, Lynch TJ, Schlessinger J, Lee J, Lifton RP, Wistuba II, Herbst RS. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up. *Ann Oncol.* 2018;29:1072.
34. Zhang YL, Sun JW, Xie YY, Zhou Y, Liu P, Song JC, Xu CH, Wang L, Liu D, Xu AN, Chen Z, Chen SJ, Sun XJ, Huang QH. Setd2 deficiency impairs hematopoietic stem cell self-renewal and causes malignant transformation. *Cell Res.* 2018;28:476–90.
35. Mar BG, Chu SH, Kahn JD, Krivtsov AV, Koche R, Castellano CA, Kotliar JL, Zon RL, McConkey ME, Chabon J, Chappell R, Grauman PV, Hsieh JJ, Armstrong SA, Ebert BL. SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia. *Blood.* 2017;130:2631–41.
36. Kim IK, McCutcheon JN, Rao G, Liu SV, Pommier Y, Skrzypski M, Zhang YW, Giaccone G. Acquired SETD2 mutation and impaired CREB1 activation confer cisplatin resistance in metastatic non-small cell lung cancer. *Oncogene.* 2018;38:180–93.
37. Li F, Mao G, Tong D, Huang J, Gu L, Yang W, Li GM. The histone mark H3K36me3 regulates human DNA mismatch repair through its interaction with MutSalpha. *Cell.* 2013;153:590–600.
38. Chen K, Liu J, Liu S, Xia M, Zhang X, Han D, Jiang Y, Wang C, Cao X. Methyltransferase SETD2-mediated methylation of STAT1 is critical for interferon antiviral activity. *Cell.* 2017;170(492–506):e414.
39. Park IY, Powell RT, Tripathi DN, Dere R, Ho TH, Blasius TL, Chiang YC, Davis IJ, Fahey CC, Hacker KE, Verhey KJ, Bedford MT, Jonasz E, Rathmell WK, Walker CL. Dual chromatin and cytoskeletal remodeling by SETD2. *Cell.* 2016;166:950–62.